Research paper

Mimicking brain tissue binding in an *in vitro* model of the blood-brain barrier illustrates differences between *in vitro* and *in vivo* methods for assessing the rate of brain penetration

Marjolein Heymans, Emmanuel Sevin, Fabien Gosselet, Stefan Lundquist, Maxime Culot

PII: S0939-6411(17)31240-7
DOI: https://doi.org/10.1016/j.ejpb.2018.03.007
Reference: EJPB 12724

To appear in: *European Journal of Pharmaceutics and Biopharmaceutics*

Received Date: 27 October 2017
Revised Date: 13 February 2018
Accepted Date: 16 March 2018

Please cite this article as: M. Heymans, E. Sevin, F. Gosselet, S. Lundquist, M. Culot, Mimicking brain tissue binding in an *in vitro* model of the blood-brain barrier illustrates differences between *in vitro* and *in vivo* methods for assessing the rate of brain penetration, *European Journal of Pharmaceutics and Biopharmaceutics* (2018), doi: https://doi.org/10.1016/j.ejpb.2018.03.007

Mimicking brain tissue binding in an *in vitro* model of the blood-brain barrier illustrates differences between *in vitro* and *in vivo* methods for assessing the rate of brain penetration

Authors: HEYMANS[1] Marjolein, SEVIN Emmanuel[1], GOSSELET Fabien[1], LUNDQUIST Stefan[2] and CULOT[1] Maxime

[1]Univ. Artois, EA 2465 - Blood-Brain Barrier Laboratory (LBHE), F-62300 Lens, France.

[2]Local DMPK department, AstraZeneca R&D, Södertälje, Sweden (this facility was discontinued in 2014).

Corresponding author:

Maxime CULOT

Address:

Univ. Artois, EA 2465 - Blood-Brain Barrier Laboratory (LBHE)

Faculté des Sciences Jean Perrin, rue Jean Souvraz, F-62300 Lens, France.

Tel: (+33)3 21 79 17 51

E-mail: *maxime.culot@univ-artois.fr*

I. Funding Statement

This work was supported by DMPK, AstraZeneca R&D, Södertälje, S-151 85, Sweden and by the European Commission under a Marie Sklodowska-Curie Innovative Training Network: BtRAIN – European Brain Barriers Training Network (H2020-MSCA-ITN-2015, n°675619).